Pharmaceutical giant Pfizer has announced that its experimental Lyme disease vaccine has demonstrated 70 percent efficacy in late-stage clinical trials, marking a significant milestone in the fight against the tick-borne illness that affects hundreds of thousands annually across North America and Europe.
The vaccine, designated VLA15, represents the first potential Lyme disease immunization to reach advanced testing phases in over two decades. Developed in partnership with Austrian biotech company Valneva, the three-dose vaccine targets the outer surface protein A (OspA) of the Borrelia burgdorferi bacteria, the primary pathogen responsible for Lyme disease.
Results from the Phase 3 trial, which enrolled approximately 6,000 participants aged 5 and older across endemic regions in the United States and Europe, showed the vaccine prevented symptomatic Lyme disease in 70 percent of cases during the primary analysis period. The efficacy rate climbed to 75 percent among adults aged 18 to 65.
The timing of these results coincides with growing concerns among public health experts about expanding tick populations and longer active seasons due to climate change. Warmer temperatures have extended the period when blacklegged ticks, the primary vector for Lyme disease, remain active and seek blood meals from humans and animals.
Lyme disease cases have tripled in the United States since the 1990s, with the Centers for Disease Control and Prevention estimating over 476,000 Americans are diagnosed and treated for the condition annually. Early symptoms include fever, headache, fatigue, and the characteristic erythema migrans rash. Without prompt antibiotic treatment, the infection can spread to joints, the heart, and the nervous system.
American media focuses on FDA approval process and rising tick activity in New England, emphasizing regional health implications
The previous Lyme vaccine, LYMErix, was withdrawn from the market in 2002 following reports of potential autoimmune side effects, though regulatory reviews never definitively established a causal link. The new vaccine candidate has shown a different safety profile in trials, with most adverse events being mild to moderate injection site reactions.
Pfizer plans to submit applications for regulatory approval to both the Food and Drug Administration and European Medicines Agency in the coming months. If approved, the vaccine would represent a crucial new tool for preventing Lyme disease, particularly for individuals living in or traveling to high-risk areas.
Public health experts emphasize that vaccination would complement, not replace, existing prevention measures such as wearing protective clothing, using insect repellents, and conducting thorough tick checks after outdoor activities in wooded or grassy areas.